Notable Tech Headlines for the Week: Nvidia, Dell, Broadcom in Focus
Earnings Scoreboard: 7 of 8 Key S&P 500 Reporting Firms Top EPS Estimates as All 8 Post Y/Y Profit Growth
Communication Services Sector Rises in August; Paramount Leads Gains
Day One of the 2026 National Reimbursement Drug List (NRDL) Negotiations: Corporate Representatives Barely Conceal Their Joy as Traditional Chinese Medicine and Chronic Disease Drugs Take Center Stage
① The first day of the 2026 national negotiations kicked off with traditional Chinese medicine (TCM) companies such as China Resources Sanjiu, Guangyuyuan, and Kangyuan Pharmaceutical taking the lead; ② In the afternoon session, Hengrui Pharma, Pfizer, and Novo-Nordisk A/S took over, initiating intensive negotiations for chronic disease medications; ③ The overall atmosphere was relatively relaxed, with corporate representatives barely concealing their satisfaction, as mechanisms like “pre-communication” have helped advance market access under the medical insurance scheme.
Catalyst Watch: Apple's High-stakes iPhone Event, Oracle, CPI, and the NFL Returns
HP Unveils New RTX Spark-Powered OmniBook AI PCs
Empowers AI builders, creators, gamers, and developers with HP's newest OmniBook PCs powered by NVIDIA RTX SparkAccelerates intelligent workflows with personal agents, local AI experiences and
9 Industrials Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity
Snowflake To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Piper
Barclays Maintains Underweight on The Campbell's, Lowers Price Target to $18
Barclays analyst Andrew Lazar maintains The Campbell's (NASDAQ:CPB) with a Underweight and lowers the price target from $19 to $18.
Jefferies Maintains Hold on The Campbell's, Lowers Price Target to $20
Jefferies analyst Scott Marks maintains The Campbell's (NASDAQ:CPB) with a Hold and lowers the price target from $22 to $20.
Blackstone and Cliffwater’s private equity funds have again triggered the 5% redemption cap, while new fundraising in the industry plummeted by 82% this year.
Blackstone’s $77 billion flagship private credit fund, BCRED, and the $31 billion Cliffwater flagship fund both hit their 5% redemption caps again in the third quarter, with redemption requests reaching 10% for the former and 16% for the latter. The industry-wide backlog of approximately $15 billion in redemptions remains difficult to resolve in the short term, while fundraising for non-traded business development companies (BDCs) plummeted by 82% this year.
Campbell's Turns Back to Price Hikes As Inflation Squeezes Margins
The Campbell's Company (NASDAQ:CPB) stock fell Thursday after the company reported mixed fourth-quarter results and issued fiscal 2027 adjusted EPS guidance below estimates.Campbell's Earnings
Wall Street Rallies as Fed's Waller Hints at September Rate Hold: Stock Market Today
U.S. stocks rallied broadly at midday Thursday, bouncing off the four-session slide that had dragged the Nasdaq 100 back below its August close, after Federal Reserve Governor Christopher Waller
Medicus Pharma Inks Global Licensing Deal With Pfizer Worth Over $1 Billion
Medicus Pharma Ltd. (NASDAQ:MDCX) secured on Wednesday an exclusive, sublicensable global license from Pfizer Inc. (NYSE:PFE) to develop, manufacture, and commercialize PF-08046031 (CD228V), an
Trucking Wildcards Include a Tight Capacity Environment, Driver Shortages, and the EPA NOx Rule
Campbell's Announces New Cost Savings Program Targeting $500M By Fiscal 2030, Says Actions Underway Include Plant Closures And Recently Completed Workforce Reductions; Q4 Restructuring Charges $52M Vs. $7M
Campbell's Announces New Cost Savings Program Targeting $500M By Fiscal 2030, Says Actions Underway Include Plant Closures And Recently Completed Workforce Reductions; Q4 Restructuring Charges $52M
The Campbell's Sees FY2027 Adj EPS $1.65-$1.80 Vs $1.85 Est
The Campbell's (NASDAQ:CPB) is looking for FY2027 Adj EPS of $1.65-$1.80 vs $1.85 analyst estimate..
The Campbell's Q4 Adj. EPS $0.39, Inline, Sales $2.137B Miss $2.146B Estimate
The Campbell's (NASDAQ:CPB) reported quarterly earnings of $0.39 per share which met the analyst consensus estimate. This is a 37.1 percent decrease over earnings of $0.62 per share from the same
Michael Burry Warns of a Private Credit 'Shell Game' That Could Leave Taxpayers on the Hook: APO, KKR, OWL In Focus
"The Big Short" investor Michael Burry is sounding the alarm over a "shell game" involving private equity, private credit and life insurers, highlighting a new academic paper that argues the
Top Wall Street Forecasters Revamp Campbell's Expectations Ahead Of Q4 Earnings
The Campbell's Company (NASDAQ:CPB) will release its fourth quarter earnings report before the opening bell on Thursday, Sept. 3.Analysts expect the Camden, New Jersey-based company to report